Crohn's Disease (CD), is considered chronic condition originating from immune disorder and with difficult clinical remission. Despite therapeutic advances it evolves frequent activity episodes leading to complications and surgical treatment. At the present it is now considered that the use of combination therapy (anti TNF alpha antibody and azathioprine) is one of the best treatment option in patients with CD. Objective: To evaluate the results of the use of combination therapy in patients with CD. Material and Methods: longitudinal and observational studies based on records of patients of both sexes coming from "Inflammatory Diseases Ambulatory".- Gastrocentro" UNICAMP. Variables analyzed: sex, age, a Montreal classification, Crohn's Disease Activity Index (CDAI), time use factors related to the discontinuation of combination therapy (treatment failure, defined as CDAI over 150 adverse effects and lack compliance) consequently the occurrence of surgery.
News published in Agência FAPESP Newsletter about the scholarship: